Combining the targeted therapy olaparib with an additional immunotherapy may improve immune response in a subgroup of patients with metastatic castration-resistant prostate cancer who responded poorly to initial treatment, ...
Sep 10, 2026
0
5
A new preclinical study has demonstrated that combining HER3-DXd with olaparib significantly improves treatment responses in lung cancer models. This combination therapy induces irreparable DNA damage in cancer cells while ...
Aug 24, 2026
0
7
When it comes to cancer, tumor suppressor genes are usually thought of as the "good guys." These genes make proteins that protect and repair DNA in cells. If they stop functioning or there's not enough, cancer risk goes up. ...
May 24, 2026
0
21
A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies—including ovarian and uterine cancers—found ...
Apr 20, 2026
0
4
A team of scientists led by the National Cancer Center Singapore (NCCS) and Duke-NUS Medical School (Duke-NUS) has found a new approach for treating some of the world's most aggressive cancers associated with BAP1 mutations. ...
Apr 2, 2026
0
16
In a new Dartmouth Cancer Center (DCC) study led by clinical researcher Tyler J. Curiel, MD, MPH, FACP, investigators found that the FDA-approved blood pressure drug telmisartan can significantly enhance the cancer-killing ...
Mar 25, 2026
0
567
A research group at the Italian Institute of Technology (IIT-Istituto Italiano di Tecnologia) has identified a candidate molecule that could improve current therapies against pancreatic cancer. The team designed the new molecule, ...
Dec 17, 2025
0
50
The immune system is a major determinant of how patients respond to standard treatments for ovarian cancer, the leading cause of death from gynecological malignancies. But little was known about how the immune landscape of ...
Jul 31, 2025
0
24
Excessive physical exercise, especially without adequate rest, can damage the human body in various ways. In severe cases, it can progress to overtraining syndrome, which is characterized by decreased performance and appetite, ...
Jul 2, 2025
0
19
QIMR Berghofer-led research in collaboration with Australian oncology company Kazia Therapeutics has found that combining the drug candidate paxalisib with immunotherapy triggered a molecular epigenetic process that prevented ...
Jun 11, 2025
0
22
